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PRACTICAL PEARL:  TB Screening and Management 
 
INTRODUCTION  2 TB manifestations  
o Latent tuberculosis (positive screening test + normal CXR) 
o Active disease  
 2 screening tests  
o Tuberculin skin test (TST) 
o Interferon-gamma release assay (IGRA) (i.e., T-spot® and 
QuantiFERON®GOLD) 
 IGRAs  
o For children > 5 years 
o Preferred screening test for BCG vaccine recipients > 5 years 
 Recent guidelines on appropriate evaluation for TB:    
http://cid.oxfordjournals.org/content/early/2016/12/08/cid.ciw694.full.pdf+html 
 
INITIAL EVALUATION 
AND MANAGEMENT 
BY PRIMARY CARE  
 Determine if screening indicated 
o Exposure to confirmed/suspected active disease 
o Suspicious clinical and/or X-ray findings 
o Recent immigration from a country with endemic TB 
o Travel histories to TB-endemic countries and/or substantial contact with 
people from such countries 
 If screening indicated, determine most appropriate test (IGRA vs. TST): 
https://redbook.solutions.aap.org/data/Books/1484/fig3-13.jpeg 
 Those with positive test: Obtain CXR to look for active disease  
 Low-risk healthy children > 5 years with positive TST and normal CXR: strongly 
consider getting IGRA before referral 
o False-positive TST results can occur for multiple reasons     
 
WHEN TO REFER  Children < 5 years 
o Exposure to active disease, regardless of TST results 
o Positive TST, regardless of CXR findings 
 Children > 5 years with indeterminate and/or positive IGRA 
 
HOW TO REFER  Contact MA DPH TB Clinic Office located at Baystate’s Mason Square Clinic: 794-
5435 
 For more urgent issues, please contact the Pediatric ID doctor on call 
 
WHAT TO EXPECT 
FROM BAYSTATE 
CHILDREN’S  
HOSPITAL VISIT 
 Current patient information, pertinent medical records, and immigration records 
(if applicable) will be requested for review prior to the visit 
 Due to the nature of some patients’ symptoms, other referrals or inpatient 
admission for additional evaluation/management may be recommended  
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